Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT
WINNING THE BID FOR THE 2026 LIANXI DISTRICT GASTRIC CANCER SCREENING AND EARLY INTERVENTION PROJECT

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

THE 2026 LIANXI DISTRICT GASTRIC CANCER SCREENING AND EARLY INTERVENTION PROJECT

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that on March 3, 2026, the Company successfully won the bid for the 2026 Lianxi District Gastric Cancer Screening and Early Intervention Project (the "**Project**"), which is the Company's first public health early cancer screening programme and also its first government procurement project in China, marking the official entry of its miRNA liquid biopsy technology into the public healthcare system and laying an important foundation for the large-scale implementation of gastric cancer early screening.

The budget for the Project is RMB8.100 million with the maximum bid price being RMB7.695 million, and it will provide early gastric cancer screening services for approximately 30,000 residents in Lianxi District, Jiujiang, Jiangxi, China. Lianxi District has a total population of approximately 418,000, and the Project covers about 8% of its population, making it the largest public health gastric cancer early screening programme in the region. The Project is expected to enhance the local early detection rate of gastric cancer and strengthen the region's cancer prevention and control framework.

INFORMATION OF INCIDENCE OF GASTRIC CANCER IN CHINA AND LIANXI DISTRICT

China has one of the highest incidences of gastric cancer globally, with gastric cancer ranking among the leading malignant tumours in terms of both incidence and mortality. The relatively low rate of early screening and the currently high proportion of diagnosis at the mid-to-late stage have created a heavy burden to the health of residents and the public healthcare system. Lianxi District, Jiujiang, is located in the northern part of Jiangxi Province, and its population is affected by risk factors such as high-salt dietary habits, frequent consumption of marinated foods and a high infection rate of Helicobacter pylori, resulting in significant challenges for gastric cancer prevention and control in the region. Among the traditional screening methods, gastro-endoscopy has a low rate of compliance and the accuracy of conventional tumor marker tests is limited, making it difficult to meet the demand for early screening in large-scale populations, and thus, there is an urgent need for efficient and widely accessible early screening technologies.

INFORMATION ON GASTROClear™ AND THE STRATEGIC SIGNIFICANCE OF THE PROJECT

Being the world-leading RNA liquid biopsy biotechnology company, the Company's core product GASTROClear™ is the first in vitro diagnostics product for gastric cancer screening in China, which obtained the Class III Medical Device Registration Certificate issued by the National Medical Products Administration (國家藥品監督管理局). It fills the gap of early screening of blood-based gastric cancer in China by virtue of its strengths of non-invasive blood draw with precision and high efficiency, and is suitable for universal screening for a large-scale population. The successful award of the Project reflects important recognition from authorities in the public health sector of the Company's technological capabilities and the strength of its products. It will also enable the Company to gain valuable practical experience in expanding into the national government procurement market, as well as support the broader implementation and promotion of similar public health early screening programmes in the future.

The successful award of the Project also reflects the Company's vision of "Stopping Cancer at an Early Stage" (把癌症攔截在早期). As the Company's first public health programme and government procurement project in China, the Company will carry out the screening services with high standards of quality, leveraging the advantages of its miRNA liquid biopsy technology to provide convenient and accurate early gastric cancer screening solutions for residents of Lianxi District and support improvements in regional public health and well-being. The Company also intends to use the Project as a model to support the broader adoption of early gastric cancer screening technologies in similar public health programmes and government procurement initiatives in other regions.

The implementation of the Project will facilitate the establishment of a closed loop of gastric cancer prevention and treatment in Lianxi District based on the principle of "screening — diagnosis — intervention — follow-up (篩查 — 診斷 — 干預 — 隨訪)", which is expected to contribute to lowering the incidence and mortality of gastric cancer in the region. The Project also represents an important milestone in the Company's commercialization efforts, supporting the translation of its research and development capabilities into positive public health outcomes. This is expected to further strengthen the Company's leading position in the field of early cancer screening and make early cancer detection services accessible to more people.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GASTROClear™ will ultimately be successfully commercialized at scale by the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, March 5, 2026

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.